International Journal of Tuberculosis and Lung Disease

Article	Citations
The impact of COVID-19 on TB: a review of the data	178
The Global Asthma Report 2022	78
Clinical standards for the assessment, management and rehabilitation of post-TB lung disease	78
Impact of COVID-19 on TB diagnosis in Northeastern Brazil	44
Post-TB health and wellbeing	36
Clinical standards for the diagnosis, treatment and prevention of TB infection	35
The COVID-19 and TB syndemic: the way forward	34
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB	30
Clinical standards for the dosing and management of TB drugs	28
The burden and determinants of post-TB lung disease	25
Diagnosing pulmonary aspergillosis is much easier than it used to be: a new diagnostic landscape	23
Persistent chronic respiratory symptoms despite TB cure is poorly correlated with lung function	23
Pulmonary TB and chronic pulmonary aspergillosis: clinical differences and similarities	22
Household air pollution and COPD: cause and effect or confounding by other aspects of poverty?	22
Comparative analysis of Truenat™ MTB Plus and Xpert® Ultra in diagnosing tuberculous meningitis	20
Thrombotic events and COVID-19 vaccines	20
The rise of artificial intelligence reading of chest X-rays for enhanced TB diagnosis and elimination	20
Impact of shelter-in-place on TB case notifications and mortality during the COVID-19 pandemic	19
Chronic obstructive pulmonary disease in sub-Saharan Africa	18
Real-world implementation of video-observed therapy in an urban TB program in the United States	18
WHO drug-resistant TB guidelines 2022: what is new?	18
TB and COVID-19 co-infection: rationale and aims of a global study	18
A randomised controlled trial to evaluate a medication monitoring system for TB treatment	18
Mortality due to TB-COVID-19 coinfection in India	17
Epidemiology, pathogenesis, clinical presentation and management of TB in patients with HIV and diabetes	17

Resource reprioritisation amid competing health risks for TB and COVID-19	17
Person-centred care in TB	17
Non-hospitalised COVID-19 patients have more frequent long COVID-19 symptoms	16
Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis	16
Management of rifampicin‐resistant TB: programme indicators and care cascade analysis in South Africa	16
TB multimorbidity: a global health challenge demanding urgent attention	16
Bedaquiline for multidrug-resistant TB in paediatric patients	15
Determining the value of TB active case-finding: current evidence and methodological considerations	15
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts	15
First molecular-based anti-TB drug resistance survey in Eritrea	14
Availability of diagnostic services and essential medicines for non‐communicable respiratory diseases in African countries	14
UNITE4TB: a new consortium for clinical drug and regimen development for TB	14
Gaps in TB preventive therapy for persons initiating antiretroviral therapy in Uganda: an explanatory sequential cascade analysis	13
Cost of TB services in healthcare facilities in Kenya (No 3)	13
Monocyte-to-lymphocyte ratio as a predictor of TB among people living with HIV	13
New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India	13
Treatment outcomes and predictive factors for multidrug-resistant TB and HIV coinfection in Rio de Janeiro State, Brazil	13
Evaluation of a lateral-flow nanoparticle fluorescence assay for TB infection diagnosis	12
The war in Ukraine and potential consequences for the TB epidemic in Europe	12
VIDAS® TB-IGRA reagents induce a CD4+ and CD8+ T-cell IFN-γ response for both TB infection and active TB	11
Detection of Mycobacterium tuberculosis cell-free DNA to diagnose TB in pediatric and adult patients	11
Clinical utility of target-based next-generation sequencing for drug-resistant TB	11
The scientific response to TB – the other deadly global health emergency	11
Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries	11
Impact of mental disorders on active TB treatment outcomes: a systematic review and meta-analysis	11
Chronic respiratory disease in adult outpatients in three African countries: a cross-sectional study	11
Minimal clinically important difference of the 6-min walking test in patients with asthma	10
Number needed to screen for TB in clinical, structural or occupational risk groups	10
Risk factors for chronic pulmonary aspergillosis in post-TB patients	10
Acceptability of levofloxacin, moxifloxacin and linezolid among children and adolescents treated for TB	10
Knowledge, attitudes and practices on childhood TB among healthcare workers	10
Depression, stigma and quality of life in people with drug-susceptible TB and drug-resistant TB in Vietnam	10
National survey on the impact of the war in Ukraine on TB diagnostics and treatment services in 2022	10
The impact of COVID-19 on the diagnosis of TB in Taiwan	10
A systematic review of the number needed to screen for active TB among people living with HIV	9
The diagnosis of lung cancer in the era of interventional pulmonology	9
Two parallel pandemics: the challenges faced by countries with COVID-19 and TB	9
QT prolongation in the STREAM Stage 1 Trial	9
Air conditioners, airborne infection prevention and air pollution in buildings in New Delhi	9
Unhealthy alcohol use independently associated with unfavorable TB treatment outcomes among Indian men	9
Diurnal variability of fine-particulate pollution concentrations: data from 14 low- and middle-income countries	9
Global Asthma Report 2022: a wake-up call to enhance care and treatment for asthma globally	9
The largest prison outbreak of TB in Western Europe investigated using whole-genome sequencing	9
Outdoor air pollution and respiratory health	9
COPD exacerbation rates are higher in non-smoker patients in India	9
Implementing 3HP vs. IPT as TB preventive treatment in Pakistan	8
Country differences and determinants of yield in programmatic migrant TB screening in four European countries	8
TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up	8
Continuous cough monitoring: a novel digital biomarker for TB diagnosis and treatment response monitoring	8
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications	8

The Asthma Drug Facility and the future management of asthma	8
Work-related interstitial lung disease: what is the true burden?	8
Impact of COVID-19 on patients with asthma	8
Health-related quality of life associates with clinical parameters in patients with NTM pulmonary disease	8
The economic burden of TB-affected households in DR Congo	7
Best practices for the care of pregnant people living with TB	7
Introduction of the Simple One-Step stool Xpert Ultra method to detect TB in children and adults	7
Treatment outcomes and safety in children with rifampicin-resistant TB	7
Clinical standards for drug-susceptible pulmonary TB	7
Cost of TB services in the public and private sectors in Georgia (No 2)	7
The 100th anniversary of bacille Calmette-Guérin (BCG) and the latest vaccines against COVID-19	7
Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19	7
Costs of TB services in India (No 1)	7
Decreased notification of TB cases during the COVID-19 pandemic	7
Complications of tuberculous meningitis and their effect on outcome in a tertiary care cohort	7
Planning for TB elimination in Lebanon	7
Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens	7
Opportunities to prevent and manage undernutrition to amplify efforts to end TB	7
Towards quality adolescent-friendly services in TB care	6
Post-TB disease: a new topic for investigation—and why it matters	6
Impact of influenza A co-infection with COVID-19	6
A comparative analysis of asthma treatment guidelines and Essential Medicine Lists in sub-Saharan Africa	6
Screening for active and latent TB among migrants in France	6
Increase in disseminated TB during the COVID‐19 pandemic	6
Continuity of TB services during the COVID-19 pandemic in China	6
Xpert® MTB/RIF Ultra performance in diagnosing paediatric pulmonary TB in gastric aspirates	6
Post-TB bronchiectasis: from pathogenesis to rehabilitation	6
Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines	6
Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB	6
The impact of COVID-19 on the TB response: data from the field	6
CAD4TB software updates: different triaging thresholds require caution by users and regulation by authorities	6
Active case‐finding in contacts of people with TB	6
Effect of 6-month vs. 8-month regimen on retreatment success for pulmonary TB	6
The effect of systematic screening of the general population on TB case notification rates	6
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB	6
Using a mobile application to improve pediatric presumptive TB identification in western Kenya	6
An Inca trail to the Holy Grail: digital medication adherence support for TB care	6
Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study	5
Sustained effect of isoniazid preventive therapy among household contacts in Brazil	5
Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus	5
Undernutrition can no longer be an afterthought for global efforts to eliminate TB	5
Time for a change: considering regimen changes in analyses of observational drug-resistant TB treatment cohort data	5
Whole-genome sequencing differentiates relapse from re-infection in TB	5
Guidance is needed to mitigate the consequences of analytic errors during antimicrobial susceptibility testing for TB	5
Trends in rifampicin and isoniazid resistance in patients with presumptive TB	5
Xpert Ultra in diagnosing extrapulmonary TB: accuracy and trace calls	5
Impact of lung function on treatment outcome in patients with TB	5
Fluoroquinolone preventive therapy for children exposed to MDR-TB	5
Determinants of treatment outcomes in patients with multidrug-resistant TB	5
COVID-19 and TB: a progression-regression conundrum	5
An approach for improving the quality of country-level TB modelling	5
TB in the elderly: clinical features and outcomes	5
Measuring TB drug levels in the hair in adults and children to monitor drug exposure and outcomes	5
Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan	5
Sputum culture conversion definitions and analytic practices for multidrug-resistant TB	5
Finding gaps in routine TB surveillance activities in Bangladesh	5
Cost of TB services: approach and summary findings of a multi-country study (Value TB)	5
Effect of malnutrition on the pharmacokinetics of anti-TB drugs in Ghanaian children	5
Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TB	5
Childhood TB in China: notification, characteristics and risk factors for outcomes, 2010–2017	5
TB in older people in Asia: why it is important	5
Incremental yield of Xpert® MTB/RIF Ultra over Xpert® MTB/RIF in the diagnosis of extrapulmonary TB	5
Atorvastatin accelerates Mycobacterium tuberculosis clearance in pulmonary TB: a randomised phase IIA trial	5
Gender differences in health-seeking behaviour, diagnosis and treatment for TB	5
How mechanistic in silico modelling can improve our understanding of TB disease and treatment	5
In Reply: How TB and COVID-19 compare: an opportunity to integrate both control programmes	4
Isoniazid preventive therapy among child contacts of TB patients, India	4
Early mortality during rifampicin-resistant TB treatment	4
Extemporaneously compounded liquid formulations of clofazimine	4
The effect of medication event reminder monitoring on treatment adherence of TB patients	4
A positive COVID-19 test is associated with high mortality in RR-TB-HIV patients	4
Adverse effects and duration of treatment of TB in Canterbury, New Zealand	4
Preventive treatment of drug-resistant TB in a rural setting	4
Digital adherence technology for TB: focus on livelihoods as well as lives	4
Prevention care cascade in people exposed to drug-resistant TB	4
Case-control study of vitamin D status and adult multidrug-resistant pulmonary TB	4
Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline	4
Completion of treatment for latent TB infection in a low prevalence setting	4
Smoked drug use in patients with TB is associated with higher bacterial burden	4
Psychological distress among TB patients in sub-Saharan Africa	4

TB screening, prevention and treatment cascade in a Malawi prison	4
Clinical standards for drug-susceptible TB in children and adolescents	4
Reducing the burden of TB among migrants to low TB incidence countries	4
The effect of incarceration on TB treatment outcomes	4
Adipokines and the risk of active TB: a nested case-control study	4
High‐resolution CT in smoking‐related interstitial lung diseases	4
Impact of COVID-19 on TB services in Korea	4
Systematic rifampicin resistance errors with Xpert® MTB/RIF Ultra: implications for regulation of genotypic assays	4
Ratios from full blood count as markers for TB diagnosis, treatment, prognosis: a systematic review	4
Prevalence, knowledge and factors associated with shisha smoking among university students in Cameroon	4
Impact of COVID-19 on TB epidemiology in South Korea	4
eHealth in TB clinical management	4
Prevalence of and risk factors for depressive symptoms in non-tuberculous mycobacterial pulmonary disease	4
Impact of the bacillary load on the accuracy of rifampicin resistance results by Xpert® MTB/RIF	4
Clinical standards for the management of adverse effects during treatment for TB	4
Impact of the COVID-19 pandemic on TB infection testing	4
Tobacco use and quitting behaviour during COVID-19 lockdown	4
The impact of smoking on TB treatment outcomes includes recurrent TB	4
Lung function decline in non-tuberculous mycobacterial pulmonary disease according to disease severity	4
Clinical standards for the diagnosis and management of asthma in low- and middle-income countries	4
Diabetes mellitus is not a predictor of poor TB treatment outcomes	4
TB testing in HIV-positive patients prior to antiretroviral treatment	4
Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting	4
How much does TB screening cost? A systematic review of economic evaluations	4
Feasibility and acceptability of asynchronous VOT among patients with MDR-TB	4
GPT-4, artificial intelligence and implications for publishing	4
Community-based TB testing as an essential part of TB recovery plans in the COVID-19 era	4
Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field	3
TB screening of Ukrainian refugees in Germany	3
Ethambutol-induced optic neuropathy in nontuberculous mycobacterial disease	3
TB in children and adolescents	3
TB research amidst the COVID-19 pandemic	3
Determinants of non-adherence to anti-TB treatment in high income, low TB incidence settings: a scoping review	3
Paediatric admissions to a TB hospital: reasons for admission, clinical profile and outcomes	3
Perceived stigma among people with TB and household contacts	3
‘One Health´ approach to end zoonotic TB	3
User perspectives on the use of X-rays and computer-aided detection for TB	3
TB preventive therapy preferences among children and adolescents	3
Infection status of contacts is not associated with severity of TB in the index case	3
Diagnostic performance of whole-genome sequencing for identifying drug-resistant TB in Thailand	3
WHO target product profiles for TB preventive treatment	3
Key messages and partnerships to raise awareness and improve outcomes for people with asthma and COPD in low- and middle-income countries	3
A systematic review of the costs of diagnosis for multidrug-resistant/extensively drug-resistant TB in different settings	3
Changes to TB care in an outpatient centre during the COVID‐19 pandemic	3
Initial experience with BPaL-based regimens to treat multidrug-resistant TB	3
TB case fatality and recurrence in a private sector cohort in Mumbai, India	3
Chronic pulmonary aspergillosis as a sequel to pulmonary TB	3
Call to action for an invigorated drive to scale up TB prevention	3
Clinical care for patients with post-TB lung disease	3
TB‐related knowledge and stigma among pregnant women in low‐resource settings	3
Updated guidelines for child and adolescent TB	3
TB and COVID-19 coinfection	3
Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova	3
Costs along the TB diagnostic pathway in Uganda	3
Assessment of asthma control in users of oral anti-asthma medications	3
Progress on indoor air quality regulation in India	3
Digital approaches to reducing TB treatment loss to follow-up	3
IGRA test for TB in COVID-19: role of corticosteroids	3
Recent developments in the diagnosis and treatment of extrapulmonary non-tuberculous mycobacterial diseases	3
Shortening MDR-TB treatment: is treating more patients with fewer drugs better?	3
Stool testing for pulmonary TB diagnosis in adults	3
A self-rated health score predicts severe disease and high mortality in patients with pulmonary TB	3
Decline in TB incidence during the COVID-19 pandemic	3
Cost of TB prevention and treatment in the Philippines in 2017	3
Impact of COVID-19 on extrapulmonary TB and the benefit of decentralised TB services	3
Epidemiology and clinical characteristics of childhood TB identified using active and passive case finding	3
Implementing the 4R and 9H regimens for TB preventive treatment in Indonesia	3
Engaging private pharmacies to help end TB in India	3
Recent epidemiological trends in extrapulmonary TB in Galicia, Spain	3
Post-COVID-19 tomographic abnormalities	3
Avoiding pitfalls in calculating the population attributable fraction of undernutrition for TB	3
Parental TB associated with offspring asthma and rhinitis	3
The Barts Health NHS Trust COVID-19 cohort: characteristics, outcomes and risk scoring of patients in East London	3
Altered drug exposures of first-line TB drugs in a moxifloxacin-containing treatment regimen	3
Concomitant pulmonary disease is common among patients with extrapulmonary TB	3
TB and chronic pulmonary aspergillosis: a few relevant points	3
Use of chest radiography screening for TB: a re-evaluation of the Kolín study	3
Prevalence of TB and health-seeking behaviour	3
TB in ageing populations: lessons from Japan and Korea	3
Demographic and socio-economic risk factors associated with self-reported TB	3
Diagnosis of paediatric TB using Xpert® MTB/RIF Ultra on fresh respiratory samples	3
Risk factors for the delayed diagnosis of extrapulmonary TB	3
Clinical effects of TB sequelae in patients with COPD	3
Cost to perform door-to-door universal sputum screening for TB in a high-burden community	3
Use of stool swabs in molecular transport media increases access to Xpert Ultra testing for TB in children	3
Diabetes mellitus and TB – finding strategies to reduce the double burden of disease	2
Post-TB lung disease in three African countries	2
Efflux pump gene expression study using RNA-seq in multidrug-resistant TB	2
Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease	2
Lack of essential medical resources leaves Africa breathless	2
Aspergillus infection is an important complication of post-TB bronchiectasis	2
Prevalence of and risk factors for respiratory symptoms in an adult urban population	2
Assessment of TB treatment on patient well-being	2
Pulmonary TB and chronic pulmonary aspergillosis	2
COVID-19 effect on TB presentation and outcome	2